证券代码：002728 证券简称：特一药业 特一药业集团股份有限公司投资者关系活动记录表 编号：2025-006 | | 特定对象调研 分析师会议 | | | --- | --- | --- | | 投资者关系活 | 媒体采访 业绩说明会 | | | 动类别 | 新闻发布会 路演活动 | | | | 现场参观 | | | | 其他 电话会议 | | | 活动参与人员 | 国盛证券：张金洋、张玉 | | | | 华鑫证券：胡博新 | | | | 山西证券：邓周宇、杜鹏程 | | | | 光大证券：王明瑞、黄素青 | | | | 申万宏源证券：张静含、凌静怡 | | | | 浙商证券：王班、吴天昊、丁健行 | | | | 东方财富证券：何玮、崔晓倩 | | | | 西南证券：杜向阳、王钰玮 | | | | 天风证券：杨松、李臻 | | | | 华安证券：谭国超、熊骥溟 | | | | 华创证券：郑辰、高初蕾、赵建韬 | | | | 东吴证券：朱国广、李倩 | | | 上市公司接待 | 董事长、总经理：许荣煌 董事、财务总监、副总经理：陈习良 | | | 人员 | 董事会秘书：许紫兰 | | | | ...

Core Viewpoint - The report from Dongwu Securities highlights that Yanghe Brewery's financial statements are showing significant improvement, with a focus on marketing transformation in response to the challenging environment in the liquor industry [1] Industry Summary - The liquor industry continues to face pressure, with a trend of increasing competition and market concentration [1] - The industry is experiencing a further differentiation trend, indicating a shift in market dynamics [1] Company Summary - Yanghe Brewery is adapting to the current environment by adjusting its operational pace, focusing on key products and markets with a strategy aimed at inventory reduction and sales promotion [1] - The company has introduced the seventh generation of its Hai Zhi Lan and high-line light bottle liquor, actively pursuing operational changes [1] - The dynamic dividend yield for Yanghe Brewery has reached 6.7%, positioning the company for both offensive and defensive strategies, maintaining a "buy" rating [1]

Core Viewpoint - The article discusses the significant leadership changes and marketing transformation at FAW Jiefang, emphasizing the urgent need to adapt to market challenges and enhance competitiveness in the commercial vehicle sector [1][4][6]. Group 1: Leadership Changes - On July 1, 2025, Yu Guangjiang was appointed as the General Manager and Party Secretary of the Marketing Headquarters, tasked with overseeing sales services, customer operations, channel development, and brand marketing [1]. - Yu's extensive experience in various roles within FAW Jiefang equips him to tackle the challenges posed by international market fluctuations and domestic economic pressures [1][4]. Group 2: Marketing Transformation - The marketing transformation is seen as a necessary evolution rather than a complete overhaul, building on previous reforms to enhance the marketing system [7]. - The transformation aims to address underperformance in sales, particularly in the medium and heavy truck segments, and to boost new energy vehicle sales [7][9]. Group 3: Organizational Restructuring - Within five days of his appointment, Yu initiated a comprehensive organizational restructuring, including a marketing transformation conference and the immediate deployment of 87 sales managers to the front lines [4][6]. - The new structure includes five major regions managed by headquarters members, enhancing coordination across marketing centers [7]. Group 4: Strategic Goals - The company has set an ambitious target of selling 300,000 vehicles for the year, focusing on maintaining leadership in traditional sales while accelerating exports and enhancing new energy vehicle sales [9]. - The strategy includes launching over 40 new models in the second half of the year, showcasing the company's commitment to innovation and market responsiveness [14][16]. Group 5: Product Development and Market Positioning - FAW Jiefang recently launched four new smart power products, achieving or exceeding industry-leading standards in key performance indicators, particularly in fuel and energy consumption [10]. - The establishment of a new company focused on after-market services aims to drive industry upgrades and create a comprehensive green service ecosystem [12].

Core Viewpoint - The company is experiencing significant revenue and profit declines in 2024, with a focus on expanding its dealer network despite challenging market conditions [1][2]. Revenue Performance - In 2024, the company's revenue, net profit attributable to the parent, and net profit excluding non-recurring items are projected to be 3.001 billion, 109 million, and 71 million yuan, respectively, representing declines of 20%, 72%, and 79% [1]. - For Q4 2024, revenue is expected to decline by 28%, with bulk and dealer sales down by 23% and 36%, respectively [2]. - In Q1 2025, revenue is projected to decline by 36%, with bulk and dealer sales down by 35% and 46%, respectively [2]. Business Structure and Strategy - The company is optimizing its business structure, with an increasing share of non-direct sales and non-residential demand, while the share of direct engineering business is decreasing [3]. - The company is actively expanding into non-residential clients such as hotels and schools, reducing reliance on new residential demand [3]. - The dealer network is expanding, with a net increase of 25,951 dealers in 2024, bringing the total to 62,518, and a further increase of 6,303 dealers in Q1 2025 [2][4]. Profitability and Margins - Short-term profitability is under pressure, with gross margins declining due to reduced revenue scale and a lower proportion of high-margin direct engineering business [3]. - The net profit margin attributable to the parent decreased by 16.9 and 3.7 percentage points in Q4 2024 and Q1 2025, respectively [3]. Growth Opportunities - The company is focusing on marketing transformation and expanding its dealer and agency channels to identify new growth points [4]. - The AAM and brand cooperation models are enhancing product offerings and improving profitability, with a significant increase in non-main business income [4]. - Projected net profits for 2025-2027 are estimated at 150 million, 220 million, and 290 million yuan, corresponding to PE ratios of 17, 11, and 9 times [4].

Investment Rating - The investment rating for the company is "Buy" and is maintained [9] Core Views - The company's revenue, net profit attributable to the parent, and net profit excluding non-recurring items for 2024 are projected to be 3.001 billion, 109 million, and 71 million respectively, representing declines of 20%, 72%, and 79% year-on-year [2][6] - The revenue for Q4 2024 is expected to be 743 million, with net profit attributable to the parent and net profit excluding non-recurring items at -55 million and -63 million respectively, indicating a 28% year-on-year decline [6] - For Q1 2025, the revenue is projected at 402 million, with net profit attributable to the parent and net profit excluding non-recurring items at 3 million and -23 million respectively, reflecting a 36% year-on-year decline [6] - The revenue is under pressure due to the macroeconomic environment, but the number of distributors continues to expand [2][6] - The company is optimizing its business structure, with an increasing proportion of cash-clearance business and non-residential demand [2][6] - Short-term profitability is under pressure, but there is a focus on marketing transformation to drive new growth points [2][6] Summary by Sections Revenue and Profitability - The company is experiencing a decline in revenue and profitability due to external economic factors, with significant drops in both net profit and net profit excluding non-recurring items for 2024 [2][6] - The revenue for Q4 2024 and Q1 2025 is expected to decline significantly, with Q4 showing a 28% drop and Q1 a 36% drop year-on-year [6] Business Structure and Growth - The company is expanding its distributor network, with a net increase of 25,951 distributors in 2024, bringing the total to 62,518, and a further increase of 6,303 in Q1 2025 [2][6] - The business structure is being optimized, with a shift towards cash-clearance and non-residential projects, reducing reliance on new residential demand [2][6] Marketing and Future Outlook - The company is actively promoting marketing changes to identify new growth opportunities, focusing on quality strategic clients and expanding distribution channels [2][6] - Future net profit projections for 2025-2027 are 150 million, 220 million, and 290 million respectively, with corresponding PE ratios of 17, 11, and 9 times [2][6]

Core Viewpoint - The company reported a significant decline in revenue and net profit for 2024, with a slight improvement in Q1 2025, indicating ongoing challenges but potential recovery signs [1][2]. Financial Performance - In 2024, the company achieved revenue of 12.386 billion yuan, a year-on-year decrease of 20.72%, and a net profit attributable to shareholders of 27 million yuan, down 96.76% [1]. - For Q4 2024, revenue was 1.952 billion yuan, a decline of 43.25%, with a net loss of 518 million yuan [1]. - In Q1 2025, revenue was 2.828 billion yuan, down 32.79%, with a net profit of 75 million yuan, a decrease of 69.80% [1]. Business Segment Performance - In Q1 2025, the pharmaceutical industrial segment generated revenue of 1.467 billion yuan, a year-on-year decline of 45.52% but a quarter-on-quarter increase of 72.57 [2]. - Revenue from the nervous system drugs increased by 14.52% year-on-year to 180 million yuan, driven by increased sales of Meifikan [2]. - The pharmaceutical commercial segment reported revenue of 1.618 billion yuan, down 15.31% year-on-year [2]. Research and Development - The company accelerated R&D project progress in 2024, with 61 projects underway, including 19 traditional Chinese medicine projects and 18 chemical drug projects [3]. - Seven products in ten specifications passed consistency evaluation, and the company obtained production approval for oxycodone sustained-release tablets [3]. Marketing and Brand Strategy - The company innovated its brand promotion strategies, targeting younger demographics through cross-industry collaborations and media partnerships [4]. - It established a comprehensive media promotion matrix, enhancing brand image and influence through collaborations with authoritative media [4]. Investment Outlook - The company forecasts revenue growth rates of 8.7%, 9.6%, and 9.4% for 2025-2027, with net profit growth rates of 1917.9%, 24.3%, and 23.8% respectively [4].

Core Insights - The company reported a revenue of 12.386 billion, a year-on-year decline of 20.72%, and a net profit attributable to shareholders of 0.027 billion, down 96.76% year-on-year [1] - The company is facing short-term performance pressure due to high inventory levels and a high base from 2023, leading to a significant drop in sales across various therapeutic areas [2] - The company is undergoing marketing transformation aimed at revitalizing its brand and improving sales performance through innovative marketing strategies and organizational restructuring [3] - The company is projected to experience revenue growth in the coming years, with expected revenues of 13.663 billion, 15.047 billion, and 16.627 billion for 2025-2027, reflecting a compound annual growth rate of approximately 10% [4] Financial Performance - In 2024, the company achieved a revenue of 12.386 billion, a decrease of 20.72% year-on-year; net profit attributable to shareholders was 0.027 billion, down 96.76% year-on-year; and non-recurring net profit was 0.039 billion, down 95.02% year-on-year [1] - In Q4 alone, the company reported a revenue of 1.952 billion, a decline of 43.25% year-on-year, with a net loss of 0.518 billion, marking a shift from profit to loss [1] Sales Performance by Therapeutic Area - The pharmaceutical segment generated sales of 7.038 billion, a year-on-year decrease of 32.25%, with notable declines in various therapeutic areas: - Respiratory medications: 2.164 billion, down 18.11% - Digestive and metabolic medications: 1.873 billion, down 35% - Anti-infective drugs: 0.964 billion, down 48.43% - Neurological medications: 0.614 billion, down 31.65% - Health products: 0.605 billion, down 28.77% - Cardiovascular medications: 0.505 billion, down 34.12% - Anti-tumor and immune-regulating drugs: 0.205 billion, down 16.49% [2] Marketing and Organizational Changes - The company is implementing a marketing transformation that includes youth-oriented branding and cross-industry promotions, such as featuring its products at London Fashion Week [3] - The organizational structure has been revised, with the establishment of a market center and sales center, and a reduction of functional departments to 16, aimed at enhancing management efficiency and employee engagement [3] Future Projections - Revenue projections for 2025-2027 are as follows: - 2025: 13.663 billion, growth of 10.31% - 2026: 15.047 billion, growth of 10.13% - 2027: 16.627 billion, growth of 10.50% - Net profit projections for the same period are: - 2025: 0.597 billion, growth of 2138.21% - 2026: 0.732 billion, growth of 22.76% - 2027: 0.861 billion, growth of 17.55% - Earnings per share (EPS) are expected to be 1.07, 1.32, and 1.55 for 2025, 2026, and 2027 respectively [4]

Core Viewpoint - The company is undergoing significant marketing transformation and organizational restructuring, which is expected to lead to long-term benefits despite short-term declines in performance [3][4]. Group 1: Share Buyback and Financial Performance - As of February 28, 2025, the company has repurchased 12,729,618 shares through the Shenzhen Stock Exchange, reflecting a commitment to enhancing shareholder value [2]. - The company forecasts a net profit of 20-25 million yuan for 2024, representing a year-on-year decline of 90.13%-92.10%, with a non-recurring net profit of 16.7-21.7 million yuan, down 91.29%-93.29% [2]. Group 2: Marketing and Sales Strategy - The company is focusing on a "foundation-building, long-term benefit" strategy, establishing a self-operated organizational structure to improve sales channel integration and pharmacy sales [3]. - Sales of the core product, cough tablets, have seen a significant decline, with 2024 sales expected to be 230 million tablets compared to over 1 billion tablets in 2023, primarily due to reduced shipments [3]. - The company has increased brand promotion efforts, particularly in new media, leading to higher sales expense ratios [3]. Group 3: Product Outlook - The cough tablets are expected to recover in sales due to their effectiveness in treating chronic bronchitis and the aging population, with a target of reaching 10 million boxes in sales over the next 3-5 years [4]. - As of January 2025, sales data indicates a recovery in cough tablet sales in pharmacies, although not yet reaching the levels of the same period in 2023 [4]. Group 4: Share Buyback Purpose - The share buyback program, approved in June 2024, aims to use repurchased shares for employee stock ownership plans, with a total funding of 70-120 million yuan and a maximum repurchase price of 12.96 yuan per share [5]. - As of February 28, 2025, the company has spent approximately 93.94 million yuan on share repurchases, indicating confidence in future growth and potential to enhance employee motivation [5].